Exelixis Inc (EXEL)

Exelixis Inc (EXEL) is a Biotechnology company in the Healthcare sector listed on the NASDAQ.

As of Oct 23, 2026: market cap $16.2B; returns 1 day -1.2%, 1 week +3.7%, 1 year +69.6%.

Exelixis Inc is an oncology-focused biotechnology company that develops and commercializes small molecule therapies targeting cancer signaling pathways. Its revenue is predominantly driven by the cabozantinib franchise, including Cabometyx (cabozantinib) for renal cell carcinoma, hepatocellular carcinoma, and other indications, and Cometriq (cabozantinib) for medullary thyroid cancer.

Groups EXEL belongs to

• Healthcare
• Shrinking Share Count
• Biotechnology
• Buying Back Stock
• Oncology
• Commercial Stage
• Commercial Stage Biotech
• Pharmaceuticals
• Cancer Therapeutics
• Life Sciences
• Drug Discovery
• Clinical Stage Biotech
• R&D

EXEL financial model: income statement, cash flow and balance sheet